RNA therapeutics are transforming modern medicine, enabling highly targeted approaches across infectious disease, cancer, genetic disorders, protein replacement, gene editing, and RNA interference. However, the efficiency, scalability, and quality of…
Read More
Gene editing is transforming the treatment of inherited diseases, but efficient and precise gene insertion has often come at the expense of cell viability, stem cell fitness, and long-term durability.…
Read More
Touchlight’s cell-free, enzymatic dbDNA manufacturing platform underpins the NEOVACC Phase I trial led...
Read More
Explore how non-viral mbDNA enables efficient gene editing in hematopoietic stem cells while preserving viability, engraftment, and long-term function—driving safer, scalable gene therapies.
Read More
Touchlight’s cell-free DNA platform offers a fundamentally different approach to DNA manufacturing—enabling the rapid, scalable, and high-quality production of enzymatically produced DNA for advanced therapies. At the core of this…
Read More
Touchlight’s Chief Scientific Officer, Dr. Jill Makin, discusses how the rapid evolution of advanced therapeutics is reshaping the industry, and why cell‑free DNA is has emerged as a foundational technology…
Read More
As cell and gene therapy scales, DNA choice matters. Learn the advantages of cell‑free DNA vs pDNA in this Q&A with Touchlight’s CSO.
Read More
This application note evaluates the in vivo performance of Touchlight’s doggybone DNA™ (dbDNA™) compared with conventional plasmid DNA when delivered using Sartorius Polyplus non‑viral delivery reagents. The study investigates how…
Read More
Explore how cell‑free DNA z‑dbDNA™ offers a faster, more flexible alternative to plasmid DNA for making RNA vaccines and therapies.
Read More
